Shionogi Inc. is the U.S. subsidiary of a 140-year-old global pharmaceutical company with headquarters in Osaka, Japan. We’re dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs.
Latest News
-
Nov. 7, 2018
Shionogi to Present Clinical Data on Mulpleta® (lusutrombopag) at the Liver Meeting® 2018 of the American Association for the Study of Liver Diseases (AASLD)
-
Oct. 25, 2018
Pivotal Trial Results for Shionogi’s Cefiderocol Published in the Lancet Infectious Diseases
-
Sep. 27, 2018
Shionogi to Present Data on Cefiderocol and Baloxavir Marboxil at IDWeek 2018